Ketamine in neuropsychiatric disorders: an update

Neuropsychopharmacology, Год журнала: 2023, Номер 49(1), С. 23 - 40

Опубликована: Июнь 20, 2023

Язык: Английский

---

Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis

American Journal of Psychiatry, Год журнала: 2025, Номер unknown

Опубликована: Янв. 29, 2025

Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review meta-analysis of the available data on its efficacy against depression suicidality well side effects. MEDLINE was searched keyword "esketamine" March 24, 2024, using PRISMA method. Data processing statistical analysis were performed R, version 4.3.3, METAFOR package. Of 1,115 articles initially identified, 87 included discussion. At weeks 2-4, randomized controlled trials mostly negative or failed; however, returned weak but significant positive effect (effect size range, 0.15-0.23 at 2-4), similar to augmentation strategies atypical antipsychotics depression. concerning not any time point. sensitivity produced same results. study findings suggest that esketamine's add-on antidepressants is modest in (similar antipsychotics) absent itself. These need be considered light abuse potential fact long-term effects are still fully known. Some alarming signs deaths emerging during testing phase discussed, along other regulatory issues.

Язык: Английский

---

Mental health challenges faced by autistic people

Nature Human Behaviour, Год журнала: 2023, Номер 7(10), С. 1620 - 1637

Опубликована: Окт. 20, 2023

Язык: Английский

---

The effects of prophylactic use of esketamine on postoperative depression and quality of life: a meta-analysis

Minerva Anestesiologica, Год журнала: 2024, Номер 90(4)

Опубликована: Март 18, 2024

INTRODUCTION: The aim of this systemic review and meta-analysis was to assess the impact prophylactic use esketamine on postoperative depression quality life in patients.EVIDENCE ACQUISITION: We searched for all articles patients after surgury electronic data bases, including PubMed, EMBASE, Cochrane Central Register Controlled Trials, Web Science, up June 2023.The included studies compared using placebo through randomized controlled trials. outcome measurements consist indicators that can reflect patients' post Risk Bias tool Review Manager 5.4 adopted risk bias.EVIDENCE SYNTHESIS: study a total 11 trials with 1447 participants. This demonstrated prophylacticuse alleviated depressive symptoms (standardized mean difference [SMD]: -0.61; 95% confidence interval [CI]: -0.96 -0.25; P=0.0008) incidence (relative [RR]:0.37;95% 0.22 0.62; P=0.0001), reducing occurrence depression, anxiety, chronic pain. Additionally, it improved sleep enhanced patients.CONCLUSIONS: Prophylactic during preoperative anesthesia period has shown significant benefits improving life. It effectively alleviate pain, as well enhance quality.

Язык: Английский

---

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review

Pharmaceutics, Год журнала: 2023, Номер 15(12), С. 2773 - 2773

Опубликована: Дек. 13, 2023

Ketamine and its enantiomers represent an innovative glutamatergic agent as a treatment for individuals with treatment-resistant depression (TRD) major depressive disorder (MDD) suicidal ideation behavior. Intranasal (IN) formulations could allow quick onset of action on symptoms well reduction in side effects by bypassing the blood–brain barrier compared administration via intravenous route. The aim this review was to provide up-to-date analysis data efficacy safety IN ketamine esketamine MDD. A systematic following PRISMA guidelines conducted. Databases (PubMed, Embase, MEDLINE, PsycINFO, Google Scholar) were searched capture articles about or This highlighted interest routes MDD patients TRD active ideation. They rapid antidepressant within first hours after administration. Nevertheless, evidence is stronger than patients. profile appears be acceptable but requires further studies, more accurate delivery device required ketamine.

Язык: Английский

---

Prevenir en suicidio. ¿Oportunidad o utopía? Revisión pragmática sobre el estado de la cuestión.

Psiquiatría Biológica, Год журнала: 2025, Номер unknown, С. 100712 - 100712

Опубликована: Фев. 1, 2025

---

Psychiatric and legal considerations for ketamine treatment within prison settings

Frontiers in Psychiatry, Год журнала: 2024, Номер 15

Опубликована: Апрель 18, 2024

The fundamental right to equivalence of health care in prison settings encompasses the provision medication address mental conditions. Considering increased risk for self-harm among individuals dealing with depression, limited effectiveness conservative antidepressants is a major challenge psychiatry. high prevalence suicidal tendencies within populations underscores imperative state-of-the-art pharmacological treatment uphold adequate standards. Notably, denial access effective could be deemed violation human rights people living according international treaties, domestic law, and United Nations normative standards detention. This article presents authors' perspective on accessibility ketamine settings, discussing psychiatric legal considerations as well current challenges this context. Implementing novel psychopharmacological interventions may alleviate distress experienced by struggling depressive symptoms suicidality. At same time, unprecedented alternatives bring along potential issues, including understanding long-term effects abuse. Given scarce data-availability, pressing need exists further research benefits risks populations.

Язык: Английский

---

Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans

Psychiatry Research, Год журнала: 2024, Номер 335, С. 115858 - 115858

Опубликована: Март 11, 2024

Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which will, or will not, respond to are lacking. Herein, we aim inform prediction models of non-response ketamine/esketamine in adults TRD. This is a retrospective analysis PHQ-9 item response data from 120 TRD who received repeated doses intravenous racemic ketamine intranasal eskatamine real-world clinic. Regression were fit patients' symptom trajectories, showing that all symptoms improved on average, depressed mood relatively faster than low energy. Principal component revealed first principal (PC) representing overall response, and second PC reflects variance across affective versus somatic subdomains. We then trained logistic regression classifiers predict (improvement PC1) better chance using baseline alone. Finally, by parametrically adjusting the classifier decision thresholds, identified optimal negative predictive value over 96%, while retaining specificity 22%. Thus, could identify 22% would not based purely their symptoms. approach rational recommendations avoid additional failures.

Язык: Английский

---

The narrative crisis model of suicide as a framework for suicide prevention

Personalized Medicine in Psychiatry, Год журнала: 2024, Номер 45-46, С. 100130 - 100130

Опубликована: Июнь 13, 2024

Язык: Английский

---

The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS)

Expert Opinion on Drug Safety, Год журнала: 2024, Номер unknown, С. 1 - 6

Опубликована: Июнь 17, 2024

Introduction Replicated evidence indicates that ketamine and esketamine reduces measures of suicidality in persons with treatment resistant depression (TRD). It remains uncertain whether susceptible individuals may experience worsening pre-existing either agent.

Язык: Английский

---